About AnnJi Pharmaceutical Co. Ltd
Dedicated to New Drug Development in Dermatology & Neurology
Meet Our Team
AnnJi has experienced, fully integrated business and R&D functional teams, capable of developing high potential new therapeutics from lead optimization to clinical proof of concept studies.
Wendy Huang, Ph.D.
Chair and CEO
Dr. Huang built a forty-year pharmaceutical career across multiple therapeutic areas, medical devices, and cosmetic products.
She has a strong track record in global product development and organizational development; lead and contributed to more than 10 market authorizations of new drug products and medical devices.
She has held R&D Leadership and executive positions in multinational companies, including GSK, Stiefel Labs, Connetics Corp., Dermik Laboratories, and Sanofi-Aventis. Most recently she served as President and CEO and took Lumosa Therapeutics IPO in Taiwan.
Lewis Yeh
CFO
Mr. Lewis Yeh has more than 30 years of experience in the field of finance and accounting, during which he has held the Chief Financial Officer position for more than 20 years; successfully accomplished public listing of CyberPower (3617) and GLOBALTEK (4566) in Taiwan (TWSE) in 2009 and 2018, respectively.
Mr. Yeh held several executive positions; include Vice President of Finance of Eastern Broadcasting Co., General Manager of Taiwan branch office of Ortega Infosystems Inc., General Manager of Operations in iROO, and Partner in AMPLE Consulting Group.
Throughout his career, Mr. Yeh was responsible for many cross-border mergers and acquisitions, and recently executed a reverse merger in Taiwan with great success. Mr. Yeh sits on the board of TBI Motion Group (4540). Mr. Yeh received his EMBA from National Taiwan University and graduated with high honor (Presidential Award). He is currently studying for his doctoral degree in National Taiwan University of Science and Technology Management Program.
Mr. Yeh is a Certified Public Accountant (CPA), a Certified Internal Auditor (CIA), a Certified Patent Agent, a financial management consultant certified by Taiwan Small & Medium Enterprises Counseling Foundation (SMECF), an International Certified Professional Trainer, as well as a Certified IRS Enrolled Agent in Taiwan.
Yiumo Michael Chan, Ph.D.
Vice President,
Research & Translational Medicine
Dr. Chan is a scientific leader in rare diseases and drug development with more than 20 years of translational and clinical research experience in academia and pharmaceutical industry.
During his drug development career, Dr. Chan initiated, led and supervised 10 translational and clinical programs in muscle, neurological, metabolic, dermatological, immune and rare diseases. In 2011, Dr. Chan Joined Ultragenyx Pharmaceutical, where he led the GNE Myopathy program from preclinical to Phase III clinical stage. In 2018, Dr. Chan became Head of Medical Research at TWi Biotechnology
Dr. Chan served on several medical advisory boards and patient advocacy organizations. He is currently on the Scientific and Medical Advisory Board of CURE Congenital Muscular Dystrophy, Association for Creatine Deficiencies and NIH ClinGen Expert Panel.
Dr. Chan received his B.Sc. and Ph.D. degrees from the University of Chicago where he discovered the genetic basis of Weber-Cockayne Epidermolysis Bullosa Simplex. He completed his post-doctoral training at Howard Hughes Medical Institute, Harvard Medical School followed by a faculty position at Geisinger Medical Center, PA.
Tzulin Yeh
Vice President,
Business Development
Tzulin Yeh graduated from the Department of Medical Technology and Graduate Institute of Immunology at National Taiwan University. She began her career with new drug development for diabetes wound healing at a biotech company. She expanded her expertise in intellectual property, intangible asset valuation, and technology transfer through the Multidisciplinary Management of Technology Program of the Ministry of Economic Affairs. Tzulin has held positions in several pharmaceutical companies, such as Mycenax Biotech, Lumosa Therapeutics, TTY Biopharm, and Blue Blood Biotech.
With more than 15 years of experience in new drug development and business development, Tzulin Yeh has a proven track record in research and development management, asset transactions, and in- and out-licensing for both protein drugs and new chemical entities. Notably, she successfully completed the out-licensing deal of Taiwan’s first self-innovated drug.
She excels in creating flexible business models that enable new drug development companies to secure funding in the early stages of clinical development, facilitating the progression of drug development projects to achieve significant milestones.
Dennis Huang, M.D.
Head of Clinical Research & Medical Affairs
Dr. Dennis Huang believes that innovation promotes human health and wellbeing, and this belief motivates him on his career journey of clinical development over 2 decades. During his tenure at Boehringer Ingelheim Global Clinical Development, Dr. Huang’s responsibilities encompassed first-in-Asia phase I trials, first-in-human phase I trials, late-stage trial planning, safety oversight, and clinical development lead for new chemical entity, new biological entity, and biosimilar to oversee global clinical trial conduct over Europe, USA, and Asia. Prior to AnnJi, Dr. Huang was responsible for Medical Affairs and Clinical Affairs in MSD and Intuitive, respectively.
Dr. Huang graduated from the National Taiwan University School of Medicine and completed his residency at the National Taiwan University Hospital (NTUH), Taipei, Taiwan. Dr Huang is a board-certified physician for internal medicine, medical oncology, and hematology. Before joining the industry, Dr Huang served as an attending physician at the Department of Oncology, NTUH.
Anne Yu, MS, RPh
Director
Project management, Regulatory Strategy & Clinical operation
Ms. Yu is the head of the Project Management and Regulation Affairs. She has worked in organizations across a broad spectrum of biopharmaceutical related industry, including Taiwan Drug Relief Foundation, China Medical University Hospital (as clinical pharmacist), Taiwan Supra Integration & Incubation Center (Si2C), and TWI Biotechnology.
Ms. Yu is proficient in early evaluation and managing drug development project, CMO/CRO outsourcing, government grants, as well as devising regulatory strategies to facilitate and expedite clinical trials and market authorization of new drug products.
Ms. Yu is a graduate of National Taiwan University with a BS in Pharmacy and MS in Clinical Pharmacology.
Nick Li, Ph.D.
Director
Pharmaceutical Development
Dr. Li is specialized in the design and development of oral, topical and parenteral dosage forms for pharmaceutical and biotechnology products; building on his tenure with Lumosa Therapeutics, TTY Pharmaceuticals, and Standard Chem & Pharm Co. He has hands-on experience in analytical method development, formulation development and CDMO management.
Dr. Li received a Ph.D. in Pharmaceutics from the National Cheng Kung University.
Shinyu Lai, Ph.D.
Pharmaceutical Development
Dr. Lai has extensive experience in synthetic chemistry and computer-aided drug design. He has designed and synthesized hundreds of target-specific, druggable compounds, including antiviral quasi-drugs, multi-target compounds for Alzheimer’s disease, anti-autoimmune small molecules and compounds for the treatment of male erectile dysfunction. Dr. Lai worked as a senior researcher at the National Taiwan University Innovative Drug Research Center prior to join Annji.
Dr. Lai holds a BS in Pharmacy from Taipei Medical University, and a Ph.D. from the Pharmacy School of National Taiwan University.
Tsung-Pin Andrew Pai, Ph.D.
Research And Translational Medicine
Dr. Pai is a highly skilled professional in the field of translational medicine, with extensive experience in integrating techniques and developing disease animal models.
Dr. Pai played a key role in establishing the 3D imaging platform for drug screening at AbbVie, as well as developing disease animal models for St. Anne’s University Hospital Brno. In addition, Dr. Pai led the drug screening program in PITDC, which was successfully funded by DoIT.
After receiving Ph.D. degree in Biotechnology from National Tsing Hua University, Dr. Pai was awarded with EMBO Long-Term Fellowship for his postdoctoral research at Science Academy of Austria, where Dr. Pai dedicated himself to techniques integration and transfer.
Taiwan’s leading new drug developer in dermatology & neurology
Translation and development of new chemical entities from lead optimization, candidate selection to clinical proof-of-concept
